Rheumatic Diseases Clinical Trial
Official title:
Vertebral Fracture and Osteonecrosis of the Femoral Head Associated With High-dose Glucocorticoid Therapy
Osteoporotic vertebral fracture (VF) and osteonecrosis of the femoral head (OFH) are major concerns in patients with systemic rheumatic diseases treated with high-dose glucocorticoids (GCs). The investigators examined and compared the incidence and risk factors of VF with those of OFH in patients who had recently received high-dose GC therapy to clarify the relationship between these two complications.
Patients with rheumatic diseases receiving GCs (≧0.5 mg/kg/day for prednisolone equivalent)
within the past 2 months were enrolled in this study, and treated with 200 mg/day of
etidronate cyclically. The bone mineral density (BMD) of lumbar spines (L2-4) was examined by
QDR2000. OFH was evaluated by magnetic resonance imaging (MRI). ClinicalTrials.gov
identifier: NCT00679978.
Forty-four patients completed the 2-year study including annual X-rays and the BMD analysis.
MRI evaluation at entry and 2 years was performed in 41 patients. The BMD values with
anteroposterior (AP) and lateral views decreased by 6.4% and 9.7% respectively in the first
year, but were stable in the second year. Eleven patients developed VF and 9 patients
developed OFH. The risk factors for VF included previous VF and a low BMD value (T score <
-1.5) of AP view at baseline with odds ratio (OR) 14.9 (95%CI 2.9-76.4), while the risk
factor for OFH was the recent maximum GC dosage (>1.2 mg/kg/day versus ≦; OR=7.7, 95%CI
1.3-45.5) and the decrease in BMD value of lateral view (>15% versus ≤; OR=6.7, 95% CI
1.2-36.1) in the first year.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04976972 -
A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation
|
N/A | |
Completed |
NCT04042792 -
Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate
|
||
Recruiting |
NCT05554029 -
Coronaphobia in Rheumatic Diseases
|
N/A | |
Completed |
NCT02944448 -
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
|
Phase 2 | |
Completed |
NCT02694796 -
Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy
|
N/A | |
Completed |
NCT02269254 -
Persona Versus NexGen
|
N/A | |
Completed |
NCT02256098 -
RSA RCT: ATTUNE™ TKA Versus PFC Sigma TKA
|
N/A | |
Completed |
NCT00642837 -
A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets
|
Phase 4 | |
Active, not recruiting |
NCT04704544 -
Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE)
|
N/A | |
Completed |
NCT05026853 -
Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice
|
N/A | |
Active, not recruiting |
NCT04631965 -
Healthcare Transition of Adolescents With Chronic Health Conditions
|
||
Recruiting |
NCT00024479 -
Natural History of Rheumatic Diseases in Minority Communities
|
||
Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
Not yet recruiting |
NCT04567576 -
Predictive Factors for COVID-19 in Rheumatology
|
||
Completed |
NCT02291471 -
Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01227694 -
Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01071447 -
Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment
|
N/A | |
Active, not recruiting |
NCT05618782 -
Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
|
Phase 2 | |
Active, not recruiting |
NCT05543642 -
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
|
Phase 4 | |
Active, not recruiting |
NCT02694185 -
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
|
N/A |